Rheumatic Heart Disease: Pathophysiology and Management | ||||
| Zagazig University Medical Journal | ||||
| Volume 31, Issue 1, January 2025, Page 135-142 PDF (505.13 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/zumj.2024.326657.3623 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Abdel Salam Elsaid Hussein Sherif1; Mohammad Gouda Mohamed1; Ilham Saeid Hasan Ahmeedah  2; Mohamed Salah Abdelbasit1
| ||||
| 1Cardiology Department, Faculty of Medicine, Zagazig University | ||||
| 2M.B.B.Ch., Faculty of Medicine Omar Al Mukhtar University, Libya | ||||
| Abstract | ||||
| Background: Rheumatic heart disease, which is frequently disregarded by the media and decision-makers, is a significant burden in poor nations where it accounts for the majority of youth cardiovascular morbidity and mortality, resulting in around 250,000 deaths annually globally. An aberrant autoimmune reaction to a group A streptococcal infection in a genetically vulnerable host causes the disease. The antecedent of rheumatic heart disease, acute rheumatic fever, can damage several organs and cause irreversible valve damage as well as heart failure. Penicillin works well to prevent the disease, but treating cases that have progressed requires a lot of resources, which makes managing disease particularly difficult in developing countries. Antibiotic prophylaxis against recurring episodes of acute rheumatic fever has thus been stressed in guidelines, and it appears to be a practical and cost-effective treatment. Conclusion: Screening populations at risk for rheumatic heart disease in endemic areas may enable early detection and focused therapy. Active surveillance using echocardiography-based screening may become crucial in this situation. | ||||
| Keywords | ||||
| Rheumatic Heart Disease; Atrial fibrillation; Endocarditis | ||||
|
Statistics Article View: 7,617 PDF Download: 496 |
||||
